My latest Mind and Matter column for the Wall Street Journal is on drug development and network analysis: Here’s a paradox. Every week seems to bring news from a research laboratory of an ingenious candidate cure about to enter clinical trials for a serious disease. Yet the productivity of drugs coming out of clinical trials has […]
Matt Ridley